Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 12:18:100141.
doi: 10.1016/j.jctube.2019.100141. eCollection 2020 Feb.

Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month

Aldar S Bourinbaiar  1 , Uyanga Batbold  2 , Yuri Efremenko  3 , Munkhburam Sanjagdorj  2 , Dmytro Butov  4 , Narantsetseg Damdinpurev  5 , Elena Grinishina  6 , Otgonbayar Mijiddorj  7 , Mikola Kovolev  8 , Khaliunaa Baasanjav  9 , Tetyana Butova  10 , Natalia Prihoda  3 , Ochirbat Batbold  11 , Larisa Yurchenko  3 , Ariungerel Tseveendorj  11 , Olga Arzhanova  3 , Erkhemtsetseg Chunt  11 , Hanna Stepanenko  10 , Nina Sokolenko  3 , Natalia Makeeva  12 , Marina Tarakanovskaya  1   13 , Vika Borisova  14 , Alan Reid  15 , Valeryi Kalashnikov  16 , Peter Nyasulu  17 , Satria A Prabowo  18 , Vichai Jirathitikal  13 , Allen I Bain  13 , Cynthia Stanford  19 , John Stanford  19
Affiliations

Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month

Aldar S Bourinbaiar et al. J Clin Tuberc Other Mycobact Dis. .

Abstract

Objective: Immunotherapy of tuberculosis (TB) to shorten treatment duration represents an unmet medical need. Orally delivered, tableted TB vaccine (V7) containing heat-killed Mycobacterium vaccae (NCTC 11659) has been demonstrated in prior clinical studies to be safe and fast-acting immune adjunct.

Methods: The outcome of Phase III trial of V7 containing 10 µg of hydrolyzed M. vaccae was evaluated in 152 patients randomized at 2:1 ratio: V7 (N = 100), placebo (N = 52). Both arms received conventional 1st or 2nd line TB drugs co-administered with daily pill of V7 or placebo.

Results: After one month mycobacterial clearance was observed in 68% (P < 0.0001) and 23.1% (P = 0.04) of patients on V7 and placebo. Stratified conversion rates in V7 recipients with drug-sensitive and multidrug-resistant TB were 86.7% and 55.6% vs 27.2% and 15% in placebo. Patients on V7 gained on average 2.4 kg (P < 0.0001) vs 0.3 kg (P = 0.18) in placebo. Improvements in hemoglobin levels, erythrocyte sedimentation rate and leukocyte counts were significantly better than in controls. Liver function tests revealed that V7 can prevent chemotherapy-induced hepatic damage.

Conclusion: Oral M. vaccae is safe, can overcome TB-associated weight loss and inflammation, reduce hepatotoxicity of TB drugs, improve sputum conversion three-fold OR 3.15; 95%CI (2.3,4.6), and cut treatment length by at least six-fold. Longer follow-up studies might be needed to further substantiate our findings (Clinicaltrials.gov: NCT01977768).

Keywords: Immunotherapy; MDR; Mycobacterium vaccae; Therapeutic vaccine; XDR.

PubMed Disclaimer

Conflict of interest statement

ASB, VB, MT, VK, VJ, AR and AIB are officers of Immunitor and affiliated companies. Late John Stanford and his colleague and spouse Cynthia Stanford are founders and owners of BioEos company. Remaining authors declare no conflict of interest.

Figures

Fig 1
Fig. 1
Sputum clearance percentage in V7 and placebo arms depending on TB form. Post-treatment sputum conversion rates, expressed in % on the Y-axis, among patients with DS-TB; MDR-TB; DS-TB/HIV; MDR-TB/HIV and XDR-TB after one month on V7 vs. placebo had the following P values by Fisher's exact test in 2 × 2 contingency table: P < 0.0001; P = 0.0021; P = 0.077; P = 1.0 and P = 1.0 respectively.
Fig 2
Fig. 2
The proportion of patients who responded favorably to treatment. The proportion expressed in % on Y-axis. The P values resulting from comparison of V7 vs. placebo analyzed by Chi-square 2 × 2 contingency table are as follows: HB (P = 0.015); ESR (P = 0.013); WBC (P = 0.43); Lymphocytes (P=0.45); ALT (P = 0.03); AST (P = 0.025); Bilirubin (P = 0.35); Protein (P = 0.006); Weight (P < 0.0001); BMI (P < 0.0001). The statistical analysis of other data relating to each of above shown parameter are described in detail in the Results, see paragraphs 3.3–3.8.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dubrovina I, Miskinis K, Lyepshina S, Yann Y, Hoffmann H, Zaleskis R, Nunn P, Zignol M. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int J Tuberc Lung Dis. 2008;12(7):756–762. - PubMed
    1. WHO Country Report: TB situation in Ukraine 2017 https://extranet.who.int/sree/Reports?oP=Replet&name=/WHO_HQ_Reports/G2/....
    1. Pavlenko E, Barbova A, Hovhannesyan A, Tsenilova Z, Slavuckij A, Shcherbak-Verlan B, Zhurilo A, Vitek E, Skenders G, Sela I, Cabibbe AM, Cirillo DM, de Colombani P, Dara M, Dean A, Zignol M, Dadu A. Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. Int J Tuberc Lung Dis. 2018;22(2):197–205. - PubMed
    1. WPRO Tuberculosishttp://www.wpro.who.int/mongolia/topics/tuberculosis/en/.
    1. Buyankhishig B, Naranbat N, Mitarai S, Rieder HL. Nationwide survey of anti-tuberculosis drug resistance in Mongolia. Int J Tuberc Lung Dis. 2011;15(9):1201–1205. - PubMed

Associated data